Wilshire Laboratories (Private) Limited
Private pharmaceutical manufacturer · Lahore · Pakistan
Lahore-based pharmaceutical and nutraceutical manufacturer with four decades of operations and a portfolio serving Pakistan and international markets.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Wilshire Labs (Pvt) Limited
- Company type
- Private pharmaceutical manufacturer
- Address
- 124/1, Quaid-e-Azam Industrial Estate, Kot Lakhpat, Lahore, Pakistan
- Website
- wilshirelabs.com ↗
- Phone
- +92 111 999 555
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 88%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| NEO-RISP | Risperidone | 4 mg | Tablet | 10's | 085187 | PKR 652.20 | PKR 65.22/tablet | 11% below median |
| NEO-RISP Tablet RisperidoneSource observed | — | — | — | 10's | 085184Official source ↗ | No indexed price | — | — |
| NEUMO | Levofloxacin | 250 mg | Tablet | 14s | 028765 | PKR 751.53 | PKR 53.68/tablet | 12% above median |
| NEUMO | Levofloxacin | 250 mg | Tablet | 10's | 028765 | PKR 536.81 | PKR 53.68/tablet | 12% above median |
| NEUMO | Levofloxacin | 500 mg | Tablet | 14s | 028766 | PKR 1,503.05 | PKR 107.36/tablet | 36% above median |
| NEUMO | Levofloxacin | 500 mg | Tablet | 10's | 028766 | PKR 1,073.62 | PKR 107.36/tablet | 36% above median |
| NEUMO | Levofloxacin | 750 mg | Tablet | 10's | 063131 | PKR 894.68 | PKR 89.47/tablet | Near median |
| ONWIL | Ondansetron | 4 mg | Tablet | 10s | 099818 | PKR 694.62 | PKR 69.46/tablet | 25% below median |
| Optik | Cefuroxime | 250 mg | Injection | 5's | 071374 | PKR 250.51 | PKR 50.10/vial/unit | 8% below median |
| Optik | Cefuroxime | 1.5 g | Injection | 1's | 071386 | PKR 342.15 | PKR 342.15/vial/unit | Near median |
| Optik | Cefuroxime | 750 mg | Injection | 1's | 071387 | PKR 190.08 | PKR 190.08/vial/unit | Near median |
| PALZIC | Moxifloxacin | 400 mg | Tablet | 5's | 055310 | PKR 849.95 | PKR 169.99/tablet | 8% below median |
| PALZIC | Moxifloxacin | 400 mg | Tablet | 10s | 055310 | PKR 1,665.88 | PKR 166.59/tablet | 10% below median |
| PARACETAMOL | Paracetamol | 500 mg | Tablet | 20x10's | 006386 | PKR 727.01 | PKR 3.64/tablet | Near median |
| PARACETAMOL | Paracetamol | 500 mg | Tablet | 1000's | 006386 | PKR 1,352.21 | PKR 1.35/tablet | 63% below median |
| PHENOJECT | Phenobarbital | 200 mg/mL | Injection | 1mlx10 | 086370 | PKR 163.49 | PKR 16.35/mL | 44% above median |
| PHENOTAB | Phenobarbital | 30 mg | Tablet | 60s | 006392 | PKR 51.38 | PKR 0.86/tablet | Near median |
| PHENOTAB | Phenobarbital | 30 mg | Tablet | 1000's | 006392 | PKR 895.27 | PKR 0.90/tablet | Near median |
| PHENOTAB | Phenobarbital | 30 mg | Tablet | 100s | 006392 | PKR 85.64 | PKR 0.86/tablet | Near median |
| PHENOTAB | Phenobarbital | 30 mg | Tablet | 500's | 006392 | PKR 411.05 | PKR 0.82/tablet | 8% below median |
| PRONTO | Oseltamivir | 75 mg | Capsule | 10's | 041902 | PKR 2,146.38 | PKR 214.64/capsule | 78% above median |
| QONZA | Morphine | 10 mg | Tablet | 30's | 071221 | PKR 760.33 | PKR 25.34/tablet | Near median |
| QONZA | Morphine | 10 mg | Tablet | 10's | 071221 | PKR 222.42 | PKR 22.24/tablet | 14% below median |
| QONZA | Morphine | 10 mg | Tablet | 20's | 071221 | PKR 444.83 | PKR 22.24/tablet | 14% below median |
| QUASH | Ciprofloxacin | 500 mg | Tablet | 10's | 006390 | PKR 579.75 | PKR 57.98/tablet | 36% above median |
| QUASH | Ciprofloxacin | 250 mg | Tablet | 10's | 016657 | PKR 333.52 | PKR 33.35/tablet | 32% above median |
| QUASH | Ciprofloxacin | 200 mg/100 mL | Injection | 50ml | 032352 | PKR 200.68 | PKR 4.01/mL | 128% above median |
| QUASH | Ciprofloxacin | 200 mg/100 mL | IV infusion | 100ml | 032352 | PKR 437.19 | PKR 4.37/mL | 94% above median |
| QUASH | Ciprofloxacin | 250 mg/5 mL | Suspension | 60ml | 071192 | PKR 304.13 | PKR 5.07/mL | Near median |
| RANKER | Clarithromycin | 125 mg/5 mL | Suspension | 60ml | 032345 | PKR 423.89 | PKR 7.06/mL | Near median |
| RANKER | Clarithromycin | 250 mg | Tablet | 1x10's | 032956 | PKR 456.20 | PKR 45.62/tablet | Near median |
| RANKER | Clarithromycin | 500 mg | Tablet | 1x10's | 032957 | PKR 845.87 | PKR 84.59/tablet | Near median |
| RANKERSource observed | Clarithromycin | — | Injection | 1's | 071572Official source ↗ | No indexed price | — | — |
| RANKERSource observed | Clarithromycin | — | Injection | 1's | 071572Official source ↗ | No indexed price | — | — |
| RELAX | Diazepam | 5 mg | Tablet | 30s | 006609 | PKR 58.39 | PKR 1.95/tablet | 45% above median |
| RELAX | Diazepam | 5 mg | Tablet | 1000's | 006609 | PKR 466.28 | PKR 0.47/tablet | 66% below median |
| REPLEN | Sodium chloride + Glucose + Potassium chloride + Trisodium citrate | 13.5 g + 2.6 g + 2.9 g + 1.5 g | Sachet | 1s | 093737 | PKR 18.50 | PKR 18.50/sachet | No comparator |
| RIPAVIR | Lopinavir + Ritonavir | 200 mg + 50 mg | Tablet | 120s | 107087 | PKR 10,338.58 | PKR 86.15/tablet | 10% below median |
| SECURE | Cefixime | 100 mg/5 mL | Suspension | 60ml | 030491 | PKR 552.49 | PKR 9.21/mL | 12% below median |
| SECURE | Cefixime | 100 mg/5 mL | Suspension | 30ml | 030491 | PKR 281.89 | PKR 9.40/mL | 10% below median |
| SECURE | Cefixime | 400 mg | Capsule | 7s | 031231 | PKR 707.17 | PKR 101.02/capsule | 10% below median |
| SECURE | Cefixime | 400 mg | Capsule | 5's | 031231 | PKR 505.12 | PKR 101.02/capsule | 10% below median |
| SECURE | Cefixime | 200 mg | Capsule | 7s | 034883 | PKR 413.33 | PKR 59.05/capsule | 6% below median |
| SECURE | Cefixime | 200 mg | Capsule | 5's | 034883 | PKR 295.24 | PKR 59.05/capsule | 6% below median |
| SEROBLOCK | Ondansetron | 8 mg | Tablet | 10s | 099819 | PKR 1,157.71 | PKR 115.77/tablet | 31% below median |
| SPURGESource observed | Cephalexin | — | Suspension | 60ml | 053639Official source ↗ | No indexed price | — | — |
| SPURGESource observed | Cephalexin | — | Suspension | 60ml | 053640Official source ↗ | No indexed price | — | — |
| SPURGE | Cephalexin | 250 mg | Capsule | 12's | 053641 | PKR 170.57 | PKR 14.21/capsule | 9% below median |
| SPURGE | Cephalexin | 500 mg | Capsule | 12's | 053642 | PKR 334.46 | PKR 27.87/capsule | 9% below median |
| Swiftax | Cefotaxime | 250 mg | Injection | 1 Vial | 025454 | PKR 94.61 | PKR 94.61/vial/unit | 10% below median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.